When doctors told Australian Greg Jefferys he had hepatitis C and the disease was destroying his liver, the devastating diagnosis was compounded by the cost of a cure.
Unable to afford Sovaldi, hailed as a miracle drug, the 61-year-old flew to India, one of a growing army of patients seeking out low-cost, life-saving medicines on the subcontinent.
Their illnesses vary — hepatitis C, cancer and HIV are among the most common — but they are almost always desperate, seeing in India their only hope to save their life or that of a loved one.
Photo: AFP
They contact underground “buyers clubs,” make the trip to India to buy from a legitimate distributor or seek out shady online pharmacies promising mail-order cures.
“The doctors told me ‘you’ve got Hepatitis C, you’ve probably got liver cancer,’” said Jefferys, a PhD student.
“The chatter was around the new generic versions of Sovaldi being released in India. I hopped on a plane to Chennai and in about two days I had an appointment with a specialist,” he said.
India earned a nickname as “the pharmacy to the developing world” for its tough stance on patents.
Successive governments have taken a view that patents should be granted only for major innovations, not updates to existing compounds — allowing domestic manufacturers to make generic versions of drugs at vastly lower cost.
Sovaldi, chemically known as sofosbuvir, is made by US pharmaceutical giant Gilead and costs US$84,000 for a 12-week cycle of treatment in the US.
Rejected for a patent in India, generic drug makers, some licensed by Gilead, produce versions such as Mylan’s MyHep, that cost less than US$900 a cycle.
“This is something I observe more and more,” said Leena Menghaney, who runs Medecins Sans Frontieres’ Access Campaign in India, which works to broaden access to drugs.
“All kinds of people and patients across the world are starting to access medicines from India. They travel themselves, or they contact a friend,” she said.
More than 130 million people live with chronic hepatitis C worldwide, according to the WHO, and 500,000 die each year from related liver diseases.
Since writing a blog, Jefferys receives 150 e-mails a day from people in the US, Britain and elsewhere asking for help.
When Loon Gangte, a Delhi-based HIV activist, was diagnosed with the virus in 1997, the price of treatment was far beyond his reach.
However, the advent of generic Indian anti-retrovirals saved his life — and made the country a global center for cheap, lifesaving HIV drugs.
Gangte is open about carrying medicines overseas for others and says in a decade he has been stopped just once, at Thai customs, and fined.
Most countries allow patients to import small amounts of medicines only for personal use.
Campaigning by activists like Gangte for better access to HIV treatments helped give rise to so-called buyers clubs, made famous by the 2013 Hollywood film.
“When I saw Dallas Buyers Club, I laughed,” said a woman who asked to be called Meera,who helps one Delhi club by ferrying drugs illegally in her suitcase whenever she travels. “I hate the term ‘drug tourism.’ This is about saving lives.”
Dinesh (not his real name), a long-time HIV campaigner, began working full-time for the same buyers club in August last year, helping people obtain medicines for a nominal fee.
He is not sure how people find him — he has no online presence — but gets requests from as far afield as Austria and Indonesia.
“My family were a bit reluctant, there is always a grey area in this, but I fear only the one above. I feel completely that this is right,” he said.
Pharmaceutical firms say India’s disregard for patents will stifle innovation or make drugs commercially unfeasible — Gilead paid US$11 billion to buy the developer of Sovaldi in 2012.
However, after losing several high-profile patent battles, it appears drugmakers can do little to combat the Indian government’s will or that of overseas patients determined to import drugs.
Gilead spokesman Nick Francis said the company was “aware such activity may occur.”
Perhaps the riskiest route is online pharmacies — a search on e-marketplace IndiaMart turns up dozens claiming to sell generics — with no guarantee against counterfeits.
However, legal channels are springing up, including Delhi-based Ikris Pharma Network, set up in August 2014, which does not sell drugs, but connects patients to genuine distributors.
Founder Praveen Sikri receives 70 calls a day from people struggling to access drugs, including generic Veenat, for cancer.
“Either the drug is not available or it is very expensive,” Sikri said. “We help the patient to get the product in a legalized manner.”
One recent e-mail is from a young man in San Francisco whose grandad desperately needs medicine for a stomach tumor.
In India, one way or another, he will probably be able to find it.
“There are many, many people doing this,” Sikri said.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) last week recorded an increase in the number of shareholders to the highest in almost eight months, despite its share price falling 3.38 percent from the previous week, Taiwan Stock Exchange data released on Saturday showed. As of Friday, TSMC had 1.88 million shareholders, the most since the week of April 25 and an increase of 31,870 from the previous week, the data showed. The number of shareholders jumped despite a drop of NT$50 (US$1.59), or 3.38 percent, in TSMC’s share price from a week earlier to NT$1,430, as investors took profits from their earlier gains
In a high-security Shenzhen laboratory, Chinese scientists have built what Washington has spent years trying to prevent: a prototype of a machine capable of producing the cutting-edge semiconductor chips that power artificial intelligence (AI), smartphones and weapons central to Western military dominance, Reuters has learned. Completed early this year and undergoing testing, the prototype fills nearly an entire factory floor. It was built by a team of former engineers from Dutch semiconductor giant ASML who reverse-engineered the company’s extreme ultraviolet lithography (EUV) machines, according to two people with knowledge of the project. EUV machines sit at the heart of a technological Cold
CHINA RIVAL: The chips are positioned to compete with Nvidia’s Hopper and Blackwell products and would enable clusters connecting more than 100,000 chips Moore Threads Technology Co (摩爾線程) introduced a new generation of chips aimed at reducing artificial intelligence (AI) developers’ dependence on Nvidia Corp’s hardware, just weeks after pulling off one of the most successful Chinese initial public offerings (IPOs) in years. “These products will significantly enhance world-class computing speed and capabilities that all developers aspire to,” Moore Threads CEO Zhang Jianzhong (張建中), a former Nvidia executive, said on Saturday at a company event in Beijing. “We hope they can meet the needs of more developers in China so that you no longer need to wait for advanced foreign products.” Chinese chipmakers are in
AI TALENT: No financial details were released about the deal, in which top Groq executives, including its CEO, would join Nvidia to help advance the technology Nvidia Corp has agreed to a licensing deal with artificial intelligence (AI) start-up Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. The world’s largest publicly traded company has paid for the right to use Groq’s technology and is to integrate its chip design into future products. Some of the start-up’s executives are leaving to join Nvidia to help with that effort, the companies said. Groq would continue as an independent company with a new chief executive, it said on Wednesday in a post on its Web
RSS